Evidence map›Paper›PMID 36825253›Full record

ArticleToxicology reports2023

The use of aflibercept (VEGF trap) in mitigating sulfur mustard-induced corneal neovascularization in a rabbit model.

Ariel Gore, Tamar Kadar, Maayan Cohen, Hila Gutman, Rellie Gez, Shlomit Dachir, Vered Horwitz

Open access · goldAbstract read
In one paragraph

Article in Toxicology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ariel GoreDepartment. of Pharmacology, Israel Institute for Biological Research, Ness Ziona 74100, Israel.
Tamar KadarDepartment. of Pharmacology, Israel Institute for Biological Research, Ness Ziona 74100, Israel.
Maayan CohenDepartment. of Pharmacology, Israel Institute for Biological Research, Ness Ziona 74100, Israel.
Hila GutmanDepartment. of Pharmacology, Israel Institute for Biological Research, Ness Ziona 74100, Israel.
Rellie GezDepartment. of Pharmacology, Israel Institute for Biological Research, Ness Ziona 74100, Israel.
Shlomit DachirDepartment. of Pharmacology, Israel Institute for Biological Research, Ness Ziona 74100, Israel.
Vered HorwitzDepartment. of Pharmacology, Israel Institute for Biological Research, Ness Ziona 74100, Israel.
Israel Institute for Biological Research · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sulfur mustard (SM)-induced ocular injury is characterized by an acute inflammatory response that may become chronic or enter a latent phase with delayed pathology. This study aimed to evaluate the efficacy of ziv-aflibercept and aflibercept in preventing and ameliorating corneal neovascularization (NV), respectively, following chemical eye exposure to SM vapor in a rabbit model. Chemical SM ocular insult was induced in the right eye of rabbits. A single application of ziv-aflibercept was administered 2 h or 9 days post-exposure. A single subconjunctival aflibercept treatment in an ocular formulation was administered 4 weeks after SM vapor exposure and subsequent to an initial 1-week treatment with 0.1 % dexamethasone. Clinical monitoring was performed 5-12 weeks post-exposure, and digital corneal pictures were taken to assess the extent of NV. The rabbits were euthanized and the corneas were processed for histological assessment. Treatment with ziv-aflibercept 2 h and 9 days post-exposure moderately reduced insult severity and partially delayed or prevented corneal NV. Aflibercept application 4 weeks post-exposure significantly reduced the extent of NV for 8 weeks. The substantial decrease in existing corneal NV in this group was confirmed by histology. These results reveal the powerful anti-angiogenic efficacy of the VEGF-trap for ameliorating existing NV as opposed to preventing NV development, revealing the ability of this treatment to mitigate corneal NV.

Indexed as

AfliberceptANOVA, analysis of variancebFGF, basic fibroblast growth factorNeovascularizationNV, neovascularizationNZW, New Zealand White rabbitOcular chemical insultOcular surfacePlGF, placental growth factorSM, sulfur mustardSulfur mustardTGF-β, transforming growth factor betaVEGF, vascular endothelial growth factor

Identifiers

PMID36825253
PMCPMC9941054
OpenAlexW4318305362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.